Sciomics GmbH

Sciomics is active in the early-phase development of novel diagnostic means for precision medicine with a focus on cancer as well as organ failure. These activities are based on our antibody microarray platform technology developed by the founders at the German Cancer Research Center (DKFZ) during the past 15 years. This platform is used for identifying novel protein biomarkers as well as for a highly-parallel verification.
In addition to the internal development activities, Sciomics offers multiplex protein analysis services for

• protein expression profiling
• combined phosphorylation and protein analysis
• drug target and biomarker discovery
• custom antibody microarray production

The service portfolio is based on the scioDiscover platform covering 900 different highly relevant proteins with more than 1,100 antibodies. This is currently the world’s most comprehensive commercially available immuno-based platform for a multiplexed protein analysis. The microarray based analysis is robust (CV < 10%), cost-efficient and only minute amounts of precious samples (e.g. 10μL plasma) are required.
Our complete sample-to-result service covers

• study design consultation
• protein extraction
• microarray experiments
• data analysis adapted to individual needs
• a study report presented in a publication ready format

Further information on the websites of BIOPRO Baden-Württemberg: